Brief: Ascentage Pharma Group International Says NMPA Approved Phase 3 Study Of Olverembatinib
05/07/2023 02:02
July 5 (Reuters) - Ascentage Pharma Group International
6855.HK :
* CENTER FOR DRUG EVALUATION OF NMPA APPROVED PHASE III
PIVOTAL
STUDY OF OLVEREMBATINIB
Further company coverage: 6855.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascentage Pharma International
See all newsBrief: Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China
China's Ascentage Pharma climbs as chairman buys shares on market
Brief: Ascentage Pharma Group International's Chairman Buys 38,630 Shares
Brief: Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 Million
China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up